于洋;项广宇;李涛;钱哲;

• 1:许昌市中心医院

摘要(Abstract)：

目的分析降纤酶结合阿加曲班对急性缺血性脑卒中(AIS)患者脑血流动力学、凝血/纤溶系统及血清神经胶质纤维酸性蛋白(GFAP)、骨桥蛋白(OPN)表达的影响。方法选取2018-03—2020-05许昌市中心医院AIS患者124例,以随机数字表分为研究组(n=62)、对照组(n=62)。在常规治疗基础上,对照组予以降纤酶,研究组予以降纤酶及阿加曲班,均治疗1周。对比分析2组疗效与治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、日常生活活动能力量表(BI)评分、大脑中动脉血流动力学[收缩期峰值血流速度(V_(max))、阻力指数(PI)、平均血流速度(V_(mean))]、凝血/纤溶系统[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤溶酶原活性(PLG)、纤维蛋白原(FIB)]、血清炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]、GFAP、OPN水平。结果研究组治疗1周后总有效率95.16%,高于对照组的79.03%(P<0.05);2组治疗1周后NIHSS评分与PI水平较治疗前降低,且研究组低于对照组,BI评分与V_(max)、V_(mean)水平均较治疗前提高,且研究组高于对照组(P<0.05);2组治疗1周后PT、APTT、FIB与血清IL-6、TNF-α、hs-CRP、GFAP、OPN水平较治疗前降低,且研究组低于对照组,PLG水平较治疗前提高,且研究组高于对照组(P<0.05)。结论降纤酶联合阿加曲班治疗AIS患者可改善脑血流动力学与凝血/纤溶系统,减轻炎症反应,下调GFAP、OPN表达,降低神经功能缺损程度,提升日常生活能力。

关键词(KeyWords)： 急性缺血性脑卒中;降纤酶;阿加曲班;脑血流动力学;凝血/纤溶系统;神经胶质纤维酸性蛋白;骨桥蛋白

Abstract:

Keywords:

基金项目(Foundation): 许昌市重大科技专项(转型升级创新专项)(编号:20180113031)

作者(Authors): 于洋;项广宇;李涛;钱哲;

参考文献(References)：

• [1] LI F,CHEN Q X,PENG B,et al.Microalbuminuria in patients with acute ischemic stroke[J].Neurol Res,2019,41(6):498-503.DOI:10.1080/01616412.2019.1576320.
• [2] 黄晶,刘颖,吴正刚,等.血清D-二聚体与急性缺血性脑卒中患者rt-PA静脉溶栓后早期神经功能改善及预后的关系[J].中国实用神经疾病杂志,2019,22(8):830-835.
• [3] KRAGLUND K L,MORTENSEN J K,DAMSBO A G,et al.Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke(TALOS)[J].Stroke,2018,49(11):2568-2576.DOI:10.1161/STROKEAHA.117.020067.
• [4] CHEN J,SUN D,LIU M,et al.Defibrinogen Therapy for Acute Ischemic Stroke:1332 Consecutive Cases[J].Sci Rep,2018,8(1):9489.DOI:10.1038/s41598-018-27856-6.
• [5] YITAO H,KEFU M,BINGSHAN T,et al.Effects of batroxobin with continuous transcranial Doppler monitoring in patients with acute cerebral stroke:a randomized controlled trial[J].Echocardiography,2014,31(10):1283-1292.DOI:10.1111/echo.12559.
• [6] HAO Z,LIU M,COUNSELL C,et al.Fibrinogen depleting agents for acute ischaemic stroke[J].Cochrane Database Syst Rev,2012(3):CD000091.DOI:10.1002/14651858.CD000091.pub2.
• [7] LIU S,LIU P,WANG P,et al.Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients[J].Med Sci Monit,2020,26:e924593.DOI:10.12659/MSM.924593.
• [8] YANG Y,ZHOU Z,PAN Y,et al.ARAIS Protocol Steering Group.Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS):Rationale and design[J].Am Heart J,2020,225:38-43.DOI:10.1016/j.ahj.2020.04.003.
• [9] NAKASE T,MOROI J,ISHIKAWA T.Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients[J].Clin Transl Med,2018,7(1):2.DOI:10.1186/s40169-017-0179-9.
• [10] SHAH N H.Letter by Shah Regarding Article,"Randomized,Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)"[J].Stroke,2017,48(9):e258.DOI:10.1161/STROKEAHA.117.018121.
• [11] BARRETO A D,GROTTA J C.Response by Barreto and Grotta to Letter Regarding Article,"Randomized,Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)"[J].Stroke,2017,48(9):e259.DOI:10.1161/STROKEAHA.117.018294.
• [12] 吴年宝.阿加曲班联合双抗治疗72h内脑梗死的疗效观察及安全性评估[J].中国实用神经疾病杂志,2020,23(5):406-410.
• [13] ZHAO X J,LI Q X,LIU T J,et al.Predictive values of CSS and NIHSS in the prognosis of patients with acute cerebral infarction[J].Medicine,2018,97(39):e12419.DOI:10.1097/MD.0000000000012419.
• [14] 陈盼,张鑫磊,刘震乾,等.丁苯酞联合依达拉奉治疗急性缺血性脑卒中对细胞凋亡的影响[J].中国实用神经疾病杂志,2019,22(15):1643-1648.
• [15] WARNER J J,HARRINGTON R A,SACCO R L,et al.Guidelines for the Early Management of Patients With Acute Ischemic Stroke:2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke[J].Stroke,2019,50(12):3331-3332.DOI:10.1161/STROKEAHA.119.027708.
• [16] BARRETO A D,FORD G A,SHEN L,et al.Randomized,Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)[J].Stroke,2017,48(6):1608-1616.DOI:10.1161/STROKEAHA.117.016720.
• [17] FROIO N L,MONTGOMERY R M,DAVID-NETO E,et al.Anticoagulation in acute ischemic stroke:A systematic search[J].Rev Assoc Med Bras (1992),2017,63(1):50-56.DOI:10.1590/1806-9282.63.01.50.
• [18] KONIGSBRüGGE O,KODER S,RIEDL J,et al.A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper-and hypocoagulability[J].Clin Exp Med,2017,17(2):251-256.DOI:10.1007/s10238-016-0417-2.
• [19] NISHI R,MANO T,KOBAYASHI Y,et al.Argatroban,Aspirin,and Clopidogrel Combination Therapy for Acute Penetrating Artery Infarction:A Pilot Study[J].Brain Nerve,2016,68(2):181-89.DOI:10.11477/mf.1416200370.
• [20] WADA T,YASUNAGA H,HORIGUCHI H,et al.Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke:Observational Nationwide Study in Japan[J].Stroke,2016,47(2):471-476.DOI:10.1161/STROKEAHA.115.011250.
• [21] PARIS C,DEREX L.Intravenous thrombolysis in ischemic stroke:Therapeutic perspectives[J].Rev Neurol (Paris),2015,171(12):866-875.DOI:10.1016/j.neurol.2015.09.002.
• [22] RAHBAR M H,DICKERSON A S,CAI C,et al.Methodological issues for designing and conducting a multicenter,international clinical trial in Acute Stroke:Experience from ARTSS-2 trial[J].Contemp Clin Trials,2015,44:139-148.DOI:10.1016/j.cct.2015.08.007.
• [23] ASADI H,YAN B,DOWLING R,et al.Advances in medical revascularisation treatments in acute ischemic stroke[J].Thrombosis,2014:714218.DOI:10.1155/2014/714218.
• [24] DE LA ROSA X,CERVERA A,KRISTOFFERSEN A K,et al.Mannose-binding lectin promotes local microvascular thrombosis after transient brain ischemia in mice[J].Stroke,2014,45(5):1453-1459.DOI:10.1161/STROKEAHA.113.004111.
• [25] LIU G,GENG J.Glial fibrillary acidic protein as a prognostic marker of acute ischemic stroke[J].Hum Exp Toxicol,2018,37(10):1048-1053.DOI:10.1177/0960327117751236.
• [26] PUSPITASARI V,GUNAWAN P Y,WIRADARMA H D,et al.Glial Fibrillary Acidic Protein Serum Level as a Predictor of Clinical Outcome in Ischemic Stroke[J].Open Access Maced J Med Sci,2019,7(9):1471-1474.DOI:10.3889/oamjms.2019.326.
• [27] OZAKI S,KURATA M,KUMON Y,et al.Plasma thrombin-cleaved osteopontin as a potential biomarker of acute atherothrombotic ischemic stroke[J].Hypertens Res,2017,40(1):61-66.DOI:10.1038/hr.2016.110.
• [28] SALá?EK M,?LECHTOVá J,PAVELK T.Heparin-Induced Thrombocytopenia after Total Knee Replacement[J].Acta Chir Orthop Traumatol Cech,2020,87(2):129-133.
• [29] ZHOU L S,LI X Q,ZHOU Z H,et al.Effect of Argatroban Combined With Dual Antiplatelet Therapy on Early Neurological Deterioration in Acute Minor Posterior Circulation Ischemic Stroke[J].Clin Appl Thromb Hemost,2020,26:1076029620904131.DOI:10.1177/1076029620904131.
• [30] BEREKASHVILI K,SOOMRO J,SHEN L,et al.Safety and Feasibility of Argatroban,Recombinant Tissue Plasminogen Activator,and Intra-Arterial Therapy in Stroke (ARTSS-IA Study)[J].J Stroke Cerebrovasc Dis,2018,27(12):3647-3651.DOI:10.1016/j.jstrokecerebrovasdis.2018.08.036.
• [31] CHEN L,CAO S,YANG J.Argatroban plus aspirin versus aspirin in acute ischemic stroke[J].Neurol Res,2018,40(10):862-867.DOI:10.1080/01616412.2018.1495882.
• [32] NAGAKANE Y,TANAKA E,ASHIDA S,et al.Safety of Dual Antiplatelet Therapy with Argatroban in Patients with Acute Ischemic Stroke[J].Brain Nerve,2018,70(5):557-562.DOI:10.11477/mf.1416201038.
• [33] OGURO H,MITAKI S,TAKAYOSHI H,et al.Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke[J].J Stroke Cerebrovasc Dis,2018,27(8):2175-2181.DOI:10.1016/j.jstrokecerebrovasdis.2018.03.016.